Omics Markets Projected Strong Growth Across Clinical Trials, Digital PCR Consumables, and Fluidic Samplers

Market forecasts for multiple omics-related segments point to continued expansion. The omics-based clinical trials market is on a robust growth trajectory, anticipating an increase from $31.71 billion in 2025 to $34.49 billion by 2026, with a CAGR of 8.8%, and is projected to surge to $47.78 billion by 2030. The Asia Digital PCR Gasket Consumables market is estimated at USD 95–120 million in 2026 with a projected CAGR of 12–15% through 2035, while the global multi-omic fluidic samplers market is expected to reach USD 2,757 million by 2036 from USD 1,197 million in 2026.

Drivers for the omics-based clinical trials market include the adoption of precision medicine, increased investment in data-driven trials, AI-enhanced patient recruitment, regulatory acceptance of omics endpoints, and the demand for efficient outcomes. The FDA approved 16 new personalized treatments in 2023, including oncology therapies. Pacific Biosciences of California Inc. partnered with A*STAR and Macrogen Inc. to launch a Singapore-based lab championing high-precision genomics studies. Bruker Corporation acquired Biocrates Life Sciences AG in June 2025 to enrich its multiomics solutions through metabolomics technology integration. Leading industry players include Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc., and Eli Lilly and Company. North America leads the market, yet Asia-Pacific is poised for rapid expansion. Tariffs present challenges, hiking costs for imported sequencing tools and extending study budgets, especially affecting North America and Europe's pharmaceutical sectors.

In the Asia Digital PCR Gasket Consumables market, over 70% of demand originates from clinical diagnostics (IVD) and biopharmaceutical process monitoring applications. China accounts for an estimated 40–45% of regional demand by value in 2026, followed by Japan at 25–30%. The transition from research-use-only (RUO) to regulated IVD applications is accelerating, with China's NMPA approving multiple dPCR-based liquid biopsy assays. Third-party and compatible gasket consumables are gaining traction in price-sensitive academic and CRO segments, offering 30–50% discounts relative to OEM list prices. High-precision molding tolerances (sub-10 micron) and stringent surface chemistry requirements create supply bottlenecks, with qualification cycles for new materials typically exceeding 12–18 months. Regulatory fragmentation across Asia—including divergent IVD classification systems in China, Japan, South Korea, and Southeast Asia—raises compliance costs for suppliers seeking multi-country market access.

The global multi-omic fluidic samplers market is expected to expand at a CAGR of 8.7% during the forecast period (2026 to 2036). Growth is supported by rising multi-omics research funding and precision medicine adoption, but moderated by high capital equipment costs, grant-dependent purchasing cycles in academic labs, regulatory validation requirements for clinical deployment, and substitution pressure from integrated benchtop omics platforms. The Automated Samplers segment holds a 36.5% market share in 2026 and is projected to grow at a CAGR of 9.5%, while Manual Samplers are likely to grow at 9.2%. By country, the US is projected to grow at 9.6%, China at 9.8%, and India at 11.3%. Top key players include Illumina, Inc., Thermo Fisher Scientific Inc., and Danaher Corporation.